A Single Dose Metabolism and Mass Balance Study of 14C-ABR-215050 in Healthy Subjects

An Open Label, Single Dose Metabolism and Mass Balance Study of 14C-ABR-215050 in Healthy Subjects

This is a single site, open label, single dose, non-randomized study in healthy male and female subjects. The subjects will be evaluated for plasma, urine and feces levels of 14C-ABR-215050 during 21 days.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Drug: ABR-215050

Detailed Description

As a part of the pharmacokinetic documentation, the metabolism and mass balance of 14C-ABR-215050 will be studied in healthy subjects. Female healthy subjects are included in the study in case of expanding the indication to female forms of cancer. In this study a single dose of 1.0 mg of the study drug will be administered orally as a solution under fasted conditions. The absorption and safety profiles for the oral water solution will also be documented.

• Study Type: Interventional
• Enrollment (Actual): 6
• Phase: Phase 1

Contacts and Locations

Study Locations

• Sweden
  • Linköping, Sweden, 582 25
    • JJ Berzelius Clinical Research Center AB, Berzelius Science Park

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. 40-65 year old male and female subjects.
2. Healthy according to medical history, physical examination and clinical chemistry, urine and hematological laboratory tests.
3. Body Mass Index (BMI) of 18-30.
4. Negative screen for Hepatitis B / C and HIV-infection.
5. Be willing and able to comply with the protocol for the duration of the study.
6. Women of childbearing potential must be neither pregnant nor breast-feeding. Confirmation that the subject is not pregnant must be established by a pregnancy test before the single dose and at study end. Fertile women must be willing to practice reliable methods of contraception. Medically accepted safe methods of contraception for the purpose of this study will include surgical sterilisation, intra-uterine device, diaphragm with spermicide, or condom with spermicide. As interaction studies between ABR-215050 and hormonal (oral or depot) contraceptives have not yet been performed, women using such devices must also use a complementary contraceptive device.
7. Have given written signed informed consent, prior to start of any study-related activities.

Exclusion Criteria:

1. Gastrointestinal disorders that may affect drug absorption.
2. Any vaccination within 30 days before start of this study and throughout the study.
3. Blood donation within 90 days before start of this study and for 90 days after the study.
4. Participation in other clinical studies or who have received other investigational drugs within 90 days prior to enrolment. Additionally, subjects previously included into this study and then are withdrawn from the study is not to be re-entered into the study.
5. Perform any planned surgery
6. Any use of nicotine within three (3) months before start of this study and throughout the study.
7. Known or suspected history of alcoholism or drug abuse.
8. Intake of alcoholic beverages for 24 hours prior to the administration of investigational product and for 24 hours after the dose.
9. Intake of caffeine containing beverages 10 hours prior to the administration of investigational product and for 6 hours after the dose.
10. Medication including herbal remedies (vitamins and paracetamol excluded) within 14 days before and throughout the study.

Study Plan

How is the study designed?

Design Details

• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: ABR-215050	Drug: ABR-215050; 1 mg ABR-215050; Other Names: tasquinimod

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
To establish the metabolic pattern of ABR 215050	4 months

Secondary Outcome Measures

Outcome Measure	Time Frame
To study the mass balance and to determine the disposition and pathways of elimination of 14C-ABR-215050.	4 months
To follow the safety profile	4 months

Collaborators and Investigators

• Sponsor: Active Biotech AB
• Investigators: Study Director: Marianne Ellman, BSc, Active Biotech Research AB

Study record dates

Study Major Dates

• Study Start: January 1, 2009
• Primary Completion (Actual): March 1, 2009
• Study Completion (Actual): March 1, 2009

Study Registration Dates

• First Submitted: January 8, 2010
• First Submitted That Met QC Criteria: January 12, 2010
• First Posted (Estimate): January 13, 2010

Study Record Updates

• Last Update Posted (Estimate): August 27, 2014
• Last Update Submitted That Met QC Criteria: August 26, 2014
• Last Verified: August 1, 2014

More Information

Terms related to this study

• Keywords: 14C ABR 215050 Metabolism and Mass Balance Study; tasquinimod; Metabolic pattern of 14C ABR-215050
• Other Study ID Numbers: 08TASQ09; 2008-003163-39 (EudraCT Number)